Your browser doesn't support javascript.
loading
Proteomic profiling of serum identifies a molecular signature that correlates with clinical outcomes in COPD.
Dagher, Rania; Fogel, Paul; Wang, Jingya; Soussan, David; Chiang, Chia-Chien; Kearley, Jennifer; Muthas, Daniel; Taillé, Camille; Berger, Patrick; Bourdin, Arnaud; Chenivesse, Cécile; Leroy, Sylvie; Anderson, Gary; Humbles, Alison A; Aubier, Michel; Kolbeck, Roland; Pretolani, Marina.
Afiliação
  • Dagher R; Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Fogel P; Independent Consultant, Paris, France.
  • Wang J; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Soussan D; Inserm UMR1152, Physiopathologie et Epidémiologie des Maladies Respiratoires, Université Paris Cité, Faculté de Médecine, Site Bichat, Paris, France.
  • Chiang CC; Laboratory of Excellence INFLAMEX, Université Paris-Cité, Paris, France.
  • Kearley J; Data Sciences and AI, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Muthas D; Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Taillé C; Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Berger P; Inserm UMR1152, Physiopathologie et Epidémiologie des Maladies Respiratoires, Université Paris Cité, Faculté de Médecine, Site Bichat, Paris, France.
  • Bourdin A; Laboratory of Excellence INFLAMEX, Université Paris-Cité, Paris, France.
  • Chenivesse C; Service de Pneumologie A - Groupement Hospitalier Universitaire Nord Bichat-Claude Bernard, Paris, France.
  • Leroy S; Inserm UMR1045, Université de Bordeaux, Service d'explorations Fonctionnelles Respiratoires, Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France.
  • Anderson G; Inserm UMR1046, Université de Montpellier, Département de Pneumologie et Addictologie, Centre Hospitalo-Universitaire de Montpellier, Montpellier, France.
  • Humbles AA; Inserm UMR1158, Université Pierre et Marie Curie, Service de Pneumologie et Réanimation médicale, Centre Hospitalo-Universitaire La Pitié Salpêtrière, Paris, France.
  • Aubier M; Université de Nice and Service de Pneumologie Hôpital Pasteur, Centre Hospitalo-Universitaire de Nice, Nice, France.
  • Kolbeck R; Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, Melbourne, Victoria, Australia.
  • Pretolani M; Bioscience COPD/IPF, Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, United States of America.
PLoS One ; 17(12): e0277357, 2022.
Article em En | MEDLINE | ID: mdl-36480517
ABSTRACT

OBJECTIVE:

Novel biomarkers related to main clinical hallmarks of Chronic obstructive pulmonary disease (COPD), a heterogeneous disorder with pulmonary and extra-pulmonary manifestations, were investigated by profiling the serum levels of 1305 proteins using Slow Off-rate Modified Aptamers (SOMA)scan technology.

METHODS:

Serum samples were collected from 241 COPD subjects in the multicenter French Cohort of Bronchial obstruction and Asthma to measure the expression of 1305 proteins using SOMAscan proteomic platform. Clustering of the proteomics was applied to identify disease subtypes and their functional annotation and association with key clinical parameters were examined. Cluster findings were revalidated during a follow-up visit, and compared to those obtained in a group of 47 COPD patients included in the Melbourne Longitudinal COPD Cohort.

RESULTS:

Unsupervised clustering identified two clusters within COPD subjects at inclusion. Cluster 1 showed elevated levels of factors contributing to tissue injury, whereas Cluster 2 had higher expression of proteins associated with enhanced immunity and host defense, cell fate, remodeling and repair and altered metabolism/mitochondrial functions. Patients in Cluster 2 had a lower incidence of exacerbations, unscheduled medical visits and prevalence of emphysema and diabetes. These protein expression patterns were conserved during a follow-up second visit, and substanciated, by a large part, in a limited series of COPD patients. Further analyses identified a signature of 15 proteins that accurately differentiated the two COPD clusters at the 2 visits.

CONCLUSIONS:

This study provides insights into COPD heterogeneity and suggests that overexpression of factors involved in lung immunity/host defense, cell fate/repair/ remodelling and mitochondrial/metabolic activities contribute to better clinical outcomes. Hence, high throughput proteomic assay offers a powerful tool for identifying COPD endotypes and facilitating targeted therapies.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica / Proteômica Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença Pulmonar Obstrutiva Crônica / Proteômica Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos